Immunome Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
3. Fair value measurement
The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):
| Level | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value | |
|---|---|---|---|---|---|
| Cash equivalents: | |||||
| Money market funds | 1 | $142,424 | $— | $— | $142,424 |
| Marketable securities: | |||||
| U.S. treasury securities | 2 | 124,184 | — | (24) | 124,160 |
| Total financial assets | $266,608 | $— | $(24) | $266,584 | |
| Level | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value | |
|---|---|---|---|---|---|
| Cash equivalents: | |||||
| Money market funds | 1 | $46,987 | $— | $— | $46,987 |
| U.S. treasury securities | 2 | 94,379 | 40 | — | 94,419 |
| Marketable securities: | |||||
| U.S. treasury securities | 2 | 73,935 | 17 | — | 73,952 |
| Total financial assets | $215,301 | $57 | $— | $215,358 | |
The Company’s marketable securities as of June 30, 2025 consist of U.S. treasury debt securities with a contractual maturity date of up to 4 months.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.